NT-proBNP Levels Are Reduced Following Treatment With Growth Hormone in Chronic Heart Failure Due to Ischemic Heart Disease. A Randomized Double Blind Placebo Controlled Trial

Different groups have described an impaired activity of the growth hormone (GH) / insulin-like growth factor I (IGF-I) axis in chronic heart failure (CHF) and its relation to poor clinical status and outcome. Nonetheless, the role for GH as potential therapeutic tool in HF is still controversial. NT-proBNP levels have been used to identify HF patients and correlate with both disease severity and prognosis. We sought to investigate the cardiovascular effects of GH treatment in patients with CHF due to ischemic heart disease.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research